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Deciphering the myriad ways in which proteins inter-
act with each other to give rise to complex behaviors
that define living systems is a significant challenge.
Using perturbations of DNA, genetic analyses have
provided many insights into the functions of proteins
encoded by specific genes. However, it can be difficult
to study essential genes using these approaches, and
many biological processes occur on a fast timescale
that precludes study using geneticmethods. For these
reasons and others, it is often desirable to target
proteins directly rather than the genes that encode
them. Over the past 20 years, several methods to reg-
ulate protein function have been developed. In this
review, we discuss the genesis and use of these
methods, with particular emphasis on the elements
of specificity, speed, and reversibility.
Introduction
Geneticists have taken advantage of naturally occurring
as well as engineered mutations to perturb genes and
the proteins that they encode. The knowledge harvested
from a century of these studies is truly impressive. Unbi-
ased genetic approaches (i.e., forward genetic screens)
have been incredibly useful for discovering genes that,
when mutated, give rise to identifiable phenotypes.
These correlations have provided many insights into
the functions of the proteins involved. The central
dogma of biology (DNA makes RNA makes protein)
lies at the heart of the genetic approach, so that muta-
tions affecting a specific gene are faithfully transmitted
to the protein product.
Genetic techniques can also be applied in a more tar-
geted fashion to interrogate specific proteins of interest.
This reversegeneticapproach involves mutation ofapar-
ticular gene of interest, followed by examination of the
system to evaluate the role of the candidate protein in
the process of interest. The mouse is the most complex
vertebrate in which genetic techniques are tractable. In
mice, reverse genetic studies often take the form of
a knockout strategy, whereby homologous recombina-
tion is used to inactivate a gene of interest in embryonic
stem cells. Mice derived from this procedure are hetero-
zygous, possessing one wild-type allele and one dis-
rupted allele of the gene of interest. Subsequent breed-
ing of the heterozygotes can provide homozygous
knockout (KO) mice possessing two disrupted alleles.
KO mice have proven to be powerful experimental sys-
tems for studying certain genes; however, significant ex-
perimental limitations exist.
*Correspondence: wandless@stanford.eduDisruption of a gene that is essential for development
often leads to an embryonic lethal phenotype, which ob-
viously limits the use of this approach in cases where
a less drastic phenotype is the intended subject of study
[1]. Another issue that can be even more difficult to con-
trol for is the possibility that, during development, a KO
mouse will exhibit either cellular or molecular compen-
sation for the disrupted gene [2]. Partial or complete
compensation for the missing activity can preclude de-
finitive interpretation of these experiments.
Nature tends to be parsimonious, and many proteins
perform more than one function. It can be difficult to
tease apart these different roles using basic genetic ap-
proaches. Specificity is crucial for interrogating a biolog-
ical system, but methods to rapidly and reversibly per-
turb a system can be equally important, especially for
essential genes. In order to circumvent embryonic le-
thality, methods to conditionally regulate gene function
have been developed. In microorganisms, temperature-
sensitive mutants that conditionally regulate protein
function have been extremely useful [3]. The protein
product is active and the organism is viable at the per-
missive temperature; however, moving the organism to
the nonpermissive temperature inactivates the protein
and allows observation of the phenotype. Although
powerful for microorganisms, this approach does not
translate well to vertebrates.
A variety of other methods to conditionally regulate
gene function have been developed for use in verte-
brates. Systems in which transcription of the gene of
interest is under the control of a small-molecule-
dependent promoter (e.g., tetracycline) have been used
with considerable success in both cultured cells and
whole organisms [4]. In theory, this strategy allows tran-
scription to be turned on or off to control protein levels.
At the operational level, the intrinsic stability of the pro-
tein limits the reversibility of this approach, and this fea-
ture is common to all transcriptional switches. Alter-
natively, the Cre recombinase can be used to disrupt
specific gene sequences targeted with loxP sites [5].
In a mouse, when the Cre recombinase is driven by a
tissue-specific promoter, tissue-specific disruption of
a gene of interest is possible. Unfortunately, this ap-
proach is not reversible, and in some targets, the Cre-
mediated disruption of target genes can require days
or weeks in mice [6].
Targeting DNA sequences provides exquisite specific-
ity; however, there is considerable room for improvement
in terms of speed and reversibility. Posttranscriptionally,
at least two techniques can be used to perturb mRNAs
of interest. RNA interference shows immense promise
and is currently the subject of intense study [7, 8]. Addi-
tionally, RNA regulatory elements that bind to small mol-
ecules (i.e., riboswitches) may also prove useful for
perturbing specific genes [9]. These transcriptional and
posttranscriptional strategies have been recently re-
viewed by Buskirk and Liu [10], and we will focus instead
on techniques that directly perturb protein function.
Given their long and distinguished history as therapeu-
tic agents, cell-permeable small molecules may be the
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tion. Stuart Schreiber has articulated the similarities
and differences between traditional genetic approaches
and chemical genetic strategies for investigations of
biology [11]. The use of diversity-oriented synthesis as
an engine of discovery might lead to an inhibitory (and
activating) ligand for every protein of interest. The day
may come when one can rapidly and reversibly inhibit
a specific protein without the need for any molecular bi-
ological intervention, and Nature has provided us with
several small molecules that prove the principle. It may
only be a question of time. How long will it take to assem-
ble this collection of reagents? Furthermore, what met-
rics will be used to evaluate specificity? Even with an
efficient discovery process, validating the specificity of
chemical genetic tools presents a formidable challenge.
As an alternative to the ‘‘one ligand-one protein strat-
egy’’ described above, one might build upon one or
more known protein-ligand interactions to regulate the
activity of a specific protein of interest. Properly engi-
neered, genetic fusion of a gene of interest to a sequence
encoding a ligand binding domain would produce a chi-
meric protein, the function of which could be regulated
by a cell-permeable ligand. Ideally, this strategy would
be general, so that many different proteins, either indi-
vidually or as ensembles, could be conditionally per-
turbed using a single protein-ligand system. This ‘‘one
ligand-many proteins’’ approach would require the use
of molecular biology to fuse a ligand binding domain
to the protein of interest. However, this investment
(i.e., creating transgenic or knockin cell lines or mice) re-
turns a significant dividend. Targeting the DNA ensures
the specificity of this approach, and the use of cell-
permeable ligands to perturb function provides the ele-
ments of speed and reversibility.
Properly implemented, a relatively small number of
cell-permeable ligands could be evaluated, and their in-
trinsic biological activities could be cataloged with some
confidence. In ideal cases, these cell-permeable mole-
cules would be biologically silent, so that off-target
interactions, if they exist, would not perturb cellular pro-
cesses. Biological effects would result solely from inter-
actions with the cognate ligand binding domains. In
practice, investigators may have to control for the intrin-
sic activity of the perturbing ligands. Additionally, the
requisite molecular biological interventions should be
minimal to avoid altering the function of the protein of in-
terest. A single genetic fusion to a protein of interest
might be expected to be less perturbing than two or
more artificial receptors that require posttranslational
modification and specific subcellular localization.
The development of strategies to directly control the
function of specific proteins began in the late 1980s,
and this review focuses on those systems. Not all of
the strategies allow conditional control, and not all of
the conditional systems utilize small molecules as the
regulatory agents. We will attempt to describe the con-
ceptual background of each strategy to illuminate the
different points of intervention. We will also try to point
out specific advantages and disadvantages of each ap-
proach. An ideal experimental system to conditionally
regulate protein function would be useful for any protein
of interest, predictable in its behavior and easy to imple-
ment, rapid, reversible, and specific.Hormone-Regulated Protein Function
Nuclear hormone receptors form a class of ligand-acti-
vated proteins that serve as transcription switches for
a large number of genes involved in cellular devel-
opment, differentiation, and regulation [12]. These re-
ceptors bind to hormones such as estrogen, dexameth-
asone, and progesterone, although the majority of family
members do not have known ligands. Nuclear hormone
receptors are comprised of several conserved regions,
including a DNA binding domain and a hormone binding
domain, with the hormone binding domain serving an in-
hibitory role in gene expression. Although cellular local-
ization seems to be hormone dependent for some hor-
mone receptors, with cytoplasmic localization in the
absence of hormone, and nuclear localization in its pres-
ence, several hormone receptors have been shown to
exhibit nuclear localization even in the absence of hor-
mone. The most likely scenario is that the unliganded re-
ceptor establishes an equilibrium distribution between
the cytoplasm and the nucleus, with transcriptional acti-
vation occurring only in the presence of hormone [13].
In an attempt to decouple the functions of various do-
mains of the nuclear hormone receptor, Yamamoto and
coworkers discovered that hormone binding domains
are able to control the activity of heterologous transcrip-
tion factors [14]. Initially, the authors excised the DNA
binding domain from the glucocorticoid receptor (GR)
and replaced it with the LexA DNA binding domain.
Strikingly, hormone regulation of the protein proved to
be modular, as dexamethasone regulated genes under
control of the LexA promoter. Additional studies showed
that the hormone binding domain alone was able to ex-
ert control over exogenous elements [15]. When the hor-
mone binding domain of the GR was fused to E1A, an
adenovirus transcription factor, the chimera showed
hormone-dependent activity. In the absence of hor-
mone, the promoter controlled by E1A was strongly re-
pressed, with activation observed only upon addition
of hormone (Figure 1A).
While these studies showed hormone-dependent ac-
tivation of a GR-E1A fusion protein, they also showed
that this hormonal regulation was not due entirely to
subcellular localization, as the fusion protein showed
some nuclear localization even in the absence of hor-
mone [15]. Interestingly, these studies also showed
that the ability of the hormone binding domain to repress
activity of the heterologous protein decreased as the
length of the peptide linker between the protein of inter-
est and the hormone binding domain increased, with the
length of the peptide sequence to some extent indicat-
ing a spatial separation of the two domains. It was pos-
tulated at this point and later shown that repression of
E1A activity might be due in part to association of the un-
liganded fusion protein with the chaperone Hsp90 com-
plex [16]. This finding offered an explanation for the dis-
tance dependence observed. Hsp90 associates with the
unliganded hormone binding domain, and Hsp90’s abil-
ity to sterically interfere with the function of the protein
of interest might be expected to decrease with in-
creased spatial separation.
The role of the Hsp90 complex in regulating HBD
fusions is further supported by studies of a fusion be-
tween the Myc oncogene and the estrogen receptor
HBD (Myc-ER) [17]. In the presence or absence of ligand
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Figure 1. Hormone Binding Domains Control
the Activity of Exogenous Elements in a Hor-
mone-Dependent Fashion: Depiction of Two
Possible Scenarios
(A) A hormone binding domain (HBD) fused
to a transcription factor confers hormone-
dependent activity on a promoter. Nuclear
localization signals on the HBD are obscured
by the Hsp90 complex, rendering the cyto-
plasmic transcription factor inactive. Hor-
mone binding causes an allosteric change
in the HBD that leads to dissociation of the
Hsp90 complex and subsequent transloca-
tion into the nucleus, where the transcription
factor regulates gene expression.
(B) Fusion of an HBD to a cytosolic protein of
interest (POI) confers ligand-dependence on
its activity. Association of the HBD fusion
with the Hsp90 complex precludes protein-
protein interactions between the POI and
its relevant partners. Hormone binding causes
an allosteric change in the HBD that leads to
the dissociation of the Hsp90 complex, al-
lowing the POI to interact with its relevant
substrate or binding partner.
See text for complete details.the Myc-ER fusion exhibits nuclear localization due to
signals on the Myc protein, however nuclear localization
alone is not sufficient for activity. The Myc-ER fusion pro-
tein shows activity only in the presence of estrogen, sug-
gesting that the Hsp90 complex plays a significant role in
suppressing Myc function. Thus, regulation of the hor-
mone binding domains can be regarded as a combina-
tion of subcellular localization effects as well as inhibi-
tory steric effects due to complexation with Hsp90.
The involvement of Hsp90 in protein regulation reveals
one of the shortcomings of using hormone binding do-
mains to control protein activity. While cytoplasmic
events have been controlled in this manner, the ability
of the Hsp90-associated hormone binding domain to
repress activity of the protein of interest is limited to
proteins involved in macromolecular interactions, such
as protein-DNA binding or protein-protein interactions
(Figure 1B). Indeed, enzymes, such as Ura3p, DHFR,
and galactokinase, which utilize small-molecule sub-
strates, could not be regulated by this method [18, 19].
Despite this limitation, conditional control of protein
function using hormone binding domains has been quite
successful. Activation of the protein of interest is rapid
and reversible, because activity is small-molecule de-
pendent. A variety of hormone binding domains, includ-
ing but not limited to the androgen, estrogen, glucocor-
ticoid, and progesterone receptors, can be used; thus,
several proteins could in theory be regulated indepen-
dently and specifically in the same system. Despite the
fact that these steroid ligands often possess intrinsic bi-
ological activity, this approach has been shown to work
across many cell lines and transgenic organisms, and
has allowed for conditional regulation of dozens of tran-
scription factors and kinases [19].
Stability-Based Degradation
The N-End Rule and Protein Stability
In 1986, Varshavsky and coworkers discovered that the
half-life of a protein depends, in part, upon the identity of
its N-terminal residue [20]. Chimeric proteins comprisedof an N-terminal ubiquitin domain (Ub; 76 residues) fol-
lowed by b-galactosidase were rapidly processed in
yeast by a deubiquitylating protease to yield free ubiqui-
tin plus the remainder of the fusion protein. The stability
of the liberated b-galactosidase became a function of the
newly revealed N-terminal residue, the identity of which
could be controlled via site-directed mutagenesis. It
was found that the N-terminal residues Met, Ser, Ala,
Thr, Val, and Gly led to stable proteins (t1/2 > 20 hr),
whereas the N-terminal residues Phe, Leu, Asp, Lys,
and Arg dramatically reduced the half-life of the protein
(t1/2 w2–3 min) in yeast. When Varshavsky and co-
workers attempted to test the generality of this phenom-
enon in yeast by preparing chimeric proteins with dihy-
drofolate reductase (i.e., Ub-X-DHFR), they noted that
cellular lifetimes of the X-DHFR proteins were similar, re-
gardless of the N-terminal residue [21]. This led to the re-
alization that the identity of the N-terminal amino acid is
important, but not sufficient, to confer instability to the
protein of interest.
Varshavsky’s initial results were obtained using a fu-
sion protein that contained a 45 residue linker between
the ubiquitin and b-galactosidase domains [20]. This
linker sequence was derived from an internal segment
of the lac repressor (lacI), and is not found in wild-type
b-galactosidase. Their second-generation studies using
DHFR lacked this peptide sequence [21]. When the lacI
linker was inserted between ubiquitin and DHFR (i.e.,
Ub-X-lacI-DHFR), the processed proteins showed
N-terminal-dependent stabilities similar to those ob-
served for the X-b-galactosidase proteins. A Lys-Arg-
Lys sequence found in the lacI linker is essential for its
ability to confer instability. It was shown that degrada-
tion of these proteins requires recognition by an E3 ubiq-
uitin ligase, as well as accessible lysines as sites of ubiq-
uitylation. The two lysines present in the lacI sequence
likely serve this purpose, thus increasing the rate of deg-
radation for those proteins recognized by the E3 ligase.
The polyubiquitylated proteins are then targeted for
degradation by the proteasome.
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Figure 2. Posttranslational Control of Pro-
tein Stability
(A) A destabilizing N-terminal amino acid
confers instability to a POI. Ub-Arg-POI is
cotranslationally processed to reveal a de-
stabilizing residue at the N terminus of the
POI, targeting it for ubiquitylation and degra-
dation.
(B) Temperature-sensitive DHFR fusions pro-
vide temporal and reversible control over the
function of a POI. The processed Arg-DHFR-
POI fusion is functional at the permissive
temperature, but is targeted for ubiquityla-
tion and degradation at the nonpermissive
temperature.
(C) Localization of a POI is sufficient for deg-
radation. A peptide ligand that binds to a POI
is covalently fused to the E3 ligase complex.
Association of the POI with its peptide ligand
brings the protein in close proximity to the
E3 ligase, leading to its ubiquitylation and
degradation.Following this work, Szostak and coworkers postu-
lated that the lacI peptide fragment might be sufficient
to confer instability to any number of different proteins
[22, 23]. To this end, a Ub-lacI fusion was designed as
a portable cassette that could be placed at the N termi-
nus of a protein of interest expressed in yeast. Szostak
and coworkers designed chimeric proteins in which
one cassette revealed a stabilizing Met residue upon
processing, whereas a second cassette revealed a de-
stabilizing Arg residue. As expected, the processed pro-
tein containing an N-terminal Met retained activity, and
the processed protein possessing an N-terminal Arg
showed no activity due to rapid degradation (Figure 2A).
Conditional N-End Rule
Szostak and coworkers were the first to use a portable
‘‘degron’’ to control the stability of a heterologous pro-
tein, but the approach did not offer conditional control
of protein function and, in practice, is similar to that of
a genetic KO. Varshavsky and coworkers expanded
this approach to offer temporal control and reversibility
[24]. A DHFR mutant, in which a destabilizing Arg re-
placed the wild-type N-terminal Val, was used to de-
velop a temperature-sensitive (ts) allele. Genetic selec-
tion in yeast was used to identify a mutant protein that
was stable and active at the permissive temperature
(23ºC), whereas increasing the temperature to 37ºC re-
sulted in protein degradation. The Arg-DHFRts was
then fused to Cdc28, an essential component of the
cell cycle oscillator. The Arg-DHFRts-Cdc28 fusion pro-
tein is long-lived and active at 23ºC, but phenocopies
a ts-Cdc28 allele at 37ºC (Figure 2B). These experiments
demonstrate the potential for engineering new ts alleles
for any protein of interest as long as the resulting Arg-
DHFRts fusion protein is functional. To date, this method
has been used to probe the function of multiple proteins,
including a genome-wide study of essential genes of un-
known function in fission yeast [25].
Degradation by Association
Both the Szostak and Varshavsky approaches require
that the protein of interest be targeted for degradation
by the proteasome through ubiquitylation. This goal is
achieved by fusing the protein of interest to an unstableprotein or peptide fragment that is recognized by one or
more of the enzymes involved in protein recognition and
proteasomal degradation. A more direct approach to in-
duce degradation was taken independently by Howley
and coworkers, as well as Gosink and Vierstra. Both
groups targeted proteins of interest directly to enzymes
known to be involved in proteasome-mediated protein
degradation. Gosink and Vierstra created a chimeric
protein comprised of a functional E2 domain fused to
a peptide sequence that served as a ligand for a protein
of interest [26]. Colocalization of the protein of interest
with the E2 ubiquitin-conjugating enzyme was sufficient
for monoubiquitylation under cell-free in vitro condi-
tions. Howley and coworkers used a similar approach,
in which the ligand for the protein of interest was fused
to a subunit of an E3 ligase complex (Figure 2C) [27].
These studies were successful in targeting an otherwise
stable protein for degradation in cultured mammalian
cells, with the expected phenotype observed upon deg-
radation of the target protein. This strategy of taking ad-
vantage of protein-protein interactions to noncovalently
associate a degron with a target protein has been ap-
plied for proteasome-mediated degradation using both
ubiquitin-dependent [28–30] and ubiquitin-independent
[31] mechanisms.
Taken together, these studies involving both N-end
rule-mediated degradation and localization-based deg-
radation laid the foundation for the development of gen-
eral methods for regulating protein function at the post-
translational level. These methods differ from traditional
small-molecule control of protein function and tradi-
tional temperature-sensitive alleles in that they attempt
to offer a general solution for targeting a large number
of proteins. Szostak and coworkers controlled the post-
translational stability, and therefore function, of their tar-
get protein through genetic incorporation of a degrada-
tion signal; however, their approach offers no temporal
control, and is neither tunable nor reversible. Tempera-
ture-sensitive alleles, such as those developed by Var-
shavsky and coworkers, are typically fast-acting alleles,
with responses observed on the order of minutes, but
their use is limited to systems where transition from per-
missive temperatures to nonpermissive temperatures is
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cells). Also, the response observed using ts alleles is
not tunable, and it is often unclear that the observed re-
sults are due to inactivation of the protein of interest, as
the increase in temperature can often cause changes in
the activity of off-target proteins (i.e., induction of the
heat-shock proteins). Although Gosink and Vierstra,
along with Howley and coworkers, offered a more direct
approach for targeting a protein of interest to the protea-
some, the methods inherently lack conditional control.
Small Molecules as Regulators of Protein Stability
In an effort to enhance the temporal control and gener-
ality of their DHFR ts allele, Varshavsky and coworkers
engineered a DHFR protein, the stability of which was
regulated by the high-affinity ligand, methotrexate
(MTX, Kd < 1 nM) [32, 33]. Ubiquitin-DHFR fusions con-
taining the lacI linker were prepared, which, after ubiqui-
tin processing, revealed a destabilizing Arg at the N ter-
minus of DHFR. In the absence of MTX, Arg-DHFR levels
were considerably reduced, whereas the presence of
MTX inhibited Arg-DHFR degradation. Although this
high-affinity DHFR ligand inhibited Arg-DHFR degrada-
tion, it did not inhibit recognition of the protein by an
E3 ligase, and therefore did not inhibit polyubiquitylation
of the protein.
In this scenario, it is likely that the polyubiquitylated
Arg-DHFR is targeted to the proteasome, but cannot
be degraded, as the stable protein-ligand complex pre-
cludes protein unfolding. This may create a new prob-
lem, in that the proteasome may be continually occupied
with a protein that it cannot degrade. This situation is
likely to inhibit degradation of other cellular proteins,
thereby disrupting the regulatory function of the ubiqui-
tin-proteasome system [34]. An additional difficulty in
implementing this approach in cultured mammalian cells
and vertebrates is the use of MTX as the small-molecule
regulator. As discussed, it is desirable that the regula-
tory small molecule chosen be biologically silent, but
MTX is a potent inhibitor of DHFR and nucleic acid bio-
synthesis.
Although the MTX-DHFR system was the first to at-
tempt to achieve small-molecule-dependent protein
stabilization, it was not the first example of using a bind-
ing interaction between an engineered protein and a
cell-permeable small molecule to control a cellular pro-
cess. In the early 1990’s, researchers discovered that
the natural product FK506 possessed the ability to het-
erodimerize two proteins, FKBP12 (hereafter FKBP) and
calcineurin [35]. In an example of research benefiting
from Nature’s design, a semisynthetic small molecule,
FK1012, was engineered to conditionally dimerize two
FKBP domains and any chimeras thereof [36]. This strat-
egy offered a general method for conditional control of
processes that require protein complex formation, and
has been variously used as a transcription switch [37],
a cell-death switch [38], and a control for an artificial
signaling system [39]. Among the advantages to using
the FK1012 system are the dose-dependent response
and reversibility provided by small-molecule control,
as well as FK1012’s lack of intrinsic biological activity.
FK1012’s target, FKBP, is highly abundant, yet non-
essential.One disadvantage to the FK1012 system is the diffi-
culty in controlling association of two different FKBP
chimeras, where three dimerization products are possi-
ble. For example, if protein A and protein B were individ-
ually fused to FKBP domains, the productive heterodi-
merization of proteins A and B would occur only in the
presence of FK1012. However, nonproductive homo-
dimerization of two A-FKBP fusions, as well as that of
two B-FKBP fusions, would be impossible to prevent.
Rapamycin, a natural product that simultaneously binds
to FKBP and a small domain of the TOR protein, known
as FRB, supplied a tool with which selective protein het-
erodimerization could be achieved. Proteins of interest
can be expressed as fusions to either FKBP or FRB,
and their association can be induced with rapamycin
[40]. Many methods to regulate cellular events have
taken advantage of the FKBPrapamycinFRB ternary
complex [41–47]. The system is attractive because rapa-
mycin binds very tightly to both proteins [48], and be-
cause FKBP is a highly abundant yet nonessential pro-
tein that can be found in most tissue types. However,
rapamycin’s intrinsic ability to inhibit the TOR protein
is a constant source of cellular perturbation. In rapamy-
cin-based technologies, not only does rapamycin bind
to FRB and associated fusions, but it also binds to and
inhibits TOR, leading to arrest of growth and prolifera-
tion in many cell types [40]. In mice, rapamycin is terato-
genic to developing embryos, precluding its use in such
studies [49].
In order to bypass these difficulties, rapamycin ana-
logs have been synthesized that contain large substitu-
ents at the FRB binding interface, resulting in a greatly
reduced affinity of these ‘‘bumped’’ rapamycin variants
for FRB. A triple mutant of FRB (called FRB*) with a
compensatory ‘‘hole’’ restores binding specificity for
C20-methallyl-rapamycin (MaRap) [50]. Initially, Crab-
tree and coworkers fused FRB* to GSK-3b with the
goal of using the MaRap to conditionally export GSK-
3b from the nucleus [51]. The GSK-3b-FRB* fusion was
knocked in to mice, allowing expression of the engi-
neered protein under the control of its endogenous reg-
ulatory promoter. Interestingly, the GSK-3b-FRB* fusion
protein showed lower expression levels than the other-
wise identical fusion to wild-type FRB. Furthermore,
mice homozygous for the GSK-3b-FRB* allele phe-
nocopied the conventional GSK-3b KO, which is embry-
onic-lethal. These observations suggest that the three
mutations necessary to restore MaRap binding were
detrimental to FRB* stability, and that this instability
was conferred to GSK-3b. The instability of these FRB*
fusions could be reversed by recruiting endogenous
FKBP to the GSK-3b-FRB* fusion protein using either ra-
pamycin or MaRap (Figure 3A). Finally, the kinase activ-
ity of the GSK-3b-FRB* fusion protein was restored due
to inducible stabilization by MaRap, both in cultured
cells derived from knockin mice as well as in mouse em-
bryos themselves [51].
Fusion of a protein of interest to FRB* may be a general
method with which to control protein function, as FRB*
has been shown to confer instability to a variety of pro-
teins ([51] and J.E. Gestwicki et al., submitted). The
method offers predictable, conditional, reversible, and
dose-dependent destabilization of a protein of interest;
however, the current drug of choice, MaRap, is
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Figure 3. Small-Molecule-Dependent Protein
Stability
(A) Methallyl-rapamycin (MaRap) provides
rapid, reversible, and dose-dependent regu-
lation of a POI. Instability of the FRB* mutant
is conferred to a POI, leading to proteasomal
degradation of the fusion protein. Formation
of the FKBPMaRapFRB* ternary complex
stabilizes FRB*, in turn stabilizing the POI.
(B) PROTACS provide rapid, reversible, and
dose-dependent control of function of a
POI. A PROTAC comprised of an E3 ligase
ligand conjugated to a ligand for a known
POI causes colocalization of the E3 ligase
complex and the POI. This colocalization is
sufficient for ubiquitylation and subsequent
degradation of the POI.
(C) Rapamycin allows for rapid, reversible,
and dose-dependent control of protein func-
tion. FKBP is fused to a noncatalytic subunit
of the proteasome, and FRB is fused to a
POI. Formation of the FKBPrapamycinFRB
ternary complex causes colocalization of the
POI to the proteasome, which is sufficient for
degradation of the presumably unubiquity-
lated POI.expensive, difficult to formulate, and exhibits poor phar-
macokinetic properties in vivo. Identification of new pro-
tein/ligand pairs will be necessary in order to make in
vivo studies feasible [52; this issue of Chemistry & Biol-
ogy]. Identification of multiple protein/ligand pairs might
even permit orthogonal control of multiple protein tar-
gets ([52] and J.E. Gestwicki et al., submitted).
Engineering Small-Molecule Specificity
When analyzing data from studies involving small-mole-
cule perturbation of protein function, the question of
specificity is of the utmost importance. Often, a drug
will effectively regulate the function of a protein of inter-
est, but proteomic analysis will show that it also affects
at least one, if not many, off-target proteins [53–55].
Shokat and coworkers wished to use a small molecule
to control the function of a specific protein kinase, a
task that has been particularly difficult due to the size
and homology of the protein kinase family. KOs and tra-
ditional conditional alleles have been used to study
some kinases, but these approaches have been unsuc-
cessful for kinases essential for development, or be-
cause the kinase-related events of interest occur on
a timescale faster than control of the conditional allele.
To address these issues, Shokat and coworkers de-
veloped a method by which individual kinases could
be targeted using a small molecule as either a specific
substrate or inhibitor for a specific kinase isoform [56,
57]. The approach relies on modifying the active site of
the protein of interest in such a way that the kinase main-
tains function, but can be differentiated from its family
members. Typically, this approach involves the replace-
ment of a large conserved residue in the ATP binding
site with a small glycine or alanine, thus creating a
‘‘hole’’ in the binding pocket. A known kinase inhibitor
possessing activity against many enzymes can then
be chemically modified with a large substituent, or
‘‘bump,’’ that specifically complements the mutation in-
troduced in the protein. The large substituent preventsthe inhibitor from binding to wild-type kinase family
members. This approach has been used successfully
to probe the functional roles of several ATPases and
GTPases, both in cell culture and in mice [58, 59]. The
large number of sequences within these protein families,
coupled with sequence conservation among the mem-
bers, allows this approach to be used in a general fash-
ion to interrogate many proteins using straightforward
molecular biology manipulations.
Degradation by Small-Molecule-Induced
Association
In a conceptual extension of the previously discussed
work targeting proteins of interest to E2 and E3 en-
zymes, Crews and Deshaies have collaboratively devel-
oped an approach that uses a bifunctional molecule to
mediate degradation of a protein of interest [60–62].
The bifunctional molecules, termed proteolysis target-
ing chimeric molecules (PROTACS), are heterodimeric
molecules comprised of a targeting ligand tethered to
a peptide. The targeting ligand binds to a protein of in-
terest, and the peptide sequence is a known ligand for
an E3 ligase complex. Studies show that PROTACS in-
duce colocalization of the protein of interest to the E3
ligase complex, and that formation of this ternary
complex is sufficient for ubiquitylation and subsequent
degradation of the target protein (Figure 3B). Initially,
these studies were performed using Xenopus extracts,
as the PROTACS are not cell permeable [60]. Addition
of a poly-D-arginine peptide sequence allowed the
PROTACS to enter cells, and this technique has been
shown to be effective in cultured cells [61].
Church and coworkers recently reported a comple-
mentary approach, in which proteasomal degradation
is used to control activity of a protein of interest [63].
Rather than targeting the protein of interest for ubiquity-
lation followed by degradation, the protein of interest is
targeted directly to the proteasome. Church and co-
workers fused FKBP to various noncatalytic subunits
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Figure 4. Small-Molecule-Dependent Protein
Splicing
(A) Rapamycin provides rapid, reversible,
and dose-dependent control of protein splic-
ing. An intein is divided into two fragments
(IntN and IntC) that are fused to FKBP and
FRB at the endo (nonsplicing) positions.
Two peptide or protein sequences of interest
are placed at the splicing positions. Addition
of rapamycin to form the FKBPrapamy-
cinFRB ternary complex brings the two in-
tein fragments into close proximity, which
is sufficient to facilitate splicing and covalent
ligation of the peptide sequences at the ex-
tein positions.
(B) Estrogen allows for rapid, reversible, and
dose-dependent control of protein splicing.
Both the POI and an intein are split into
two fragments, with the intein fragments sep-
arated by HBD. Addition of estrogen causes
an allosteric change in the hormone binding
domain, bringing the intein fragments into
close proximity. This colocalization allows
for intein splicing and functional reconstitu-
tion of the POI.of the proteasome, and FRB was fused to a protein of
interest. These two chimeric proteins were then ex-
pressed in yeast. In the absence of rapamycin, no inter-
action between the two proteins is observed, and the
protein of interest is stably expressed. Target protein
levels decrease when rapamycin is added, demonstrat-
ing that localization to the proteasome is sufficient for
degradation (Figure 3C). This approach could be used
to achieve rapid and reversible control of stability and
function for a wide variety of proteins, provided that
the fusion protein maintains its native activity.
While both of these methods target proteins of inter-
est for degradation, they differ in several fundamental
ways. PROTACS mediate degradation of the protein of
interest through ubiquitylation by involving both the E2
and E3 complexes and the proteasome. Church and co-
workers bypassed the ubiquitylation machinery by lo-
calizing the presumably unubiquitylated protein of inter-
est directly to the proteasome. Crews and Deshaies
point out that one strength of PROTACS is the fact
that molecular biology manipulations are unnecessary.
A known ligand for the protein of interest can simply
be covalently linked to a known E3 ligase substrate. In
the absence of a known ligand, some form of ligand dis-
covery would be required to design and synthesize the
necessary bifunctional molecule, which means that gen-
erality is limited to proteins with known high-affinity
ligands. In contrast, Church and coworkers view their
approach as a modular method to conditionally control
function of a large number of proteins through fusion
to FRB. This is certainly true to the extent that investiga-
tors can use yeast as their model organism; however,
this approach would require significant experimental in-
vestment for use in vertebrates, and rapamycin’s inhib-
itory effects on TOR would need to be addressed.
Fragment Complementation and Conditional
Protein Splicing
Recently, fragment complementation has been devel-
oped as an alternative to the yeast two-hybrid system
[64]. The yeast two-hybrid system is typically engi-neered as a transcriptional switch that requires pro-
tein-protein interactions to occur in the nucleus [65].
Fragment complementation allows direct detection of
protein-protein interactions in a wider variety of cellular
environments. For example, b-galactosidase can be
split into two noncatalytic fragments, and each fragment
can be fused to a protein of interest. When properly
crafted, b-galactosidase enzymatic activity will be re-
constituted only when the two proteins of interest
show a reasonable affinity for one another [66]. Similar
systems have been developed employing ubiquitin
[67], b-lactamase [68], DHFR [69], GFP [70], and adeny-
late cyclase [71] fragments as sensors for protein-pro-
tein interactions. Along these lines, several groups
have developed additional technologies with which to
control protein function at the posttranslational level.
Muir and coworkers have developed a method of
conditional protein splicing to control protein structure
in vitro and in mammalian cell culture [72]. During protein
splicing, an intervening sequence, termed an intein,
autocatalytically excises itself out of a precursor poly-
peptide, with concomitant linkage of the two flanking
sequences through a peptide bond. When properly de-
signed, the presence of an intein renders the precursor
polypeptide inactive, and function is restored upon pro-
tein splicing. Muir and coworkers fused two domains of
interest to the N and C termini of a cis-splicing intein.
They then divided the intein into N- and C-terminal do-
mains. At this site of division (the nonsplicing positions),
they fused FKBP to one half of the intein and FRB to the
other half, creating two separate polypeptides that can
be colocalized with rapamycin (Figure 4A). The FKBP
and FRB domains heterodimerize in the presence of ra-
pamycin, and, in turn, the intein is reconstituted due to
close proximity of the two domains. The reconstituted
intein is then able to self-splice, covalently linking the
two domains of interest.
Studies have successfully linked a target protein to an
epitope tag in cell culture, but they have not as yet re-
constituted a functional protein of interest. This method
has also been used to conditionally regulate protein
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Method Conditional Reversible General
Hormone-dependent protein function Yes Yes Limited to targets involved in macromolecular
interactions
Degron cassette based upon the N-end rule No No Yes
ts-DHFR cassette Yes Yes Limited to cultured cells or microorganisms
that can be subjected to temperature
shifts
E2/E3 localization-based degradation No No Yes
Small-Molecule-Dependent Protein Stability
FKBP-MaRap-FRB* Yes Yes Shown to be general in mice and primary
cell lines
PROTACS Yes Yes Requires a known ligand for the protein
of interest
Degradation due to localization to the
proteasome
Yes Yes Limited to yeast due to its use of rapamycin
Small-Molecule-Dependent Protein Splicing
Rapamycin-dependent intein splicing Yes Yes Depends on properties of the engineered
protein
Hormone-dependent intein splicing Yes Yes Depends on properties of the engineered
proteinkinase A when rapamycin-mediated intein splicing is
used to excise an autoinhibitory peptide [73]. One draw-
back to this technique might be the difficulty in predict-
ing appropriate cleavage sites and the necessary fusion
orientation for the protein of interest such that the pro-
tein is active when reconstituted through splicing. The
technique might also be limited by a lack of reversibility
and the fact that some fragments may be unstable or un-
able to fold outside the context of the complete protein.
Liu and coworkers took a different approach to
achieve small-molecule dependence [74]. The authors
wished to exert small-molecule control over the typically
autocatalytic process of intein splicing. To realize this
goal, an intein must acquire the ability to bind to a small
molecule, and this binding event must translate into a
signal that initiates splicing (Figure 4B). Liu and co-
workers used molecular evolution to achieve these
goals. Small-molecule dependence was conferred upon
intein splicing by inserting an estrogen binding domain
(ER) into the middle of an intein. However, simple inser-
tion of a ligand binding domain did not result in ligand-
dependent splicing.
Error-prone PCR was used to generate a library of
point-mutated intein(N)-ER-intein(C) genes, which re-
sulted in mutants that showed splicing activity both in
the presence and absence of ligand. These clones were
subjected to several additional rounds of selection and
screening to identify an intein that showed strong and
specific ligand-dependent activity. The generality of this
method was demonstrated by inserting the evolved
intein(N)-ER-intein(C) regulatory element into four differ-
ent proteins, and all four displayed small-molecule-
dependent intein excision to reconstituteprotein function.
Conclusions
Many factors contribute to the power of genetics as an
approach for studying living systems, but two particu-
larly stand out in the context of this review. First, DNA
perturbations are faithfully transmitted to the proteins
that they encode. This fact typically ensures a high de-
gree of specificity between a particular mutation andthe observed phenotype. Second, genetic approaches
usually involve the study of proteins in their natural envi-
ronments. Proteins, either wild-type or mutated, are ex-
pressed and observed in the context of a living cell or
organism. The native environment is a single cell for
microorganisms, such as bacteria and yeast. This native
environment is more heterogeneous for multicellular or-
ganisms, such as worms, flies, and mice. Regardless,
the proteins under investigation are typically expressed
in the usual quantities and are allowed to interact with
their usual partners (i.e., cofactors or other proteins).
New methods to directly interrogate protein function
should try to achieve the same goal: perturbations of
specific proteins in their natural environments.
In a sense, large-scale genome sequencing efforts
have provided life scientists with parts lists for various
organisms of interest. One of our current challenges,
and it is likely to be a challenge for some time, is to learn
how all of these parts interact with each other to give rise
to the complex systems that govern life. If the successes
of genetics have been an inspiration, then one way of
approaching this formidable challenge would be to per-
turb the system of interest and monitor the results of one
or more perturbations. However, a detailed understand-
ing of these systems will require new tools for interroga-
tion. We will need to invent new ways to specifically per-
turb proteins, and these methods will ideally allow
perturbation of function that is rapid and reversible.
In the near term, several of the modular approaches
discussed in this review appear to be attractive tech-
niques for regulating the function of specific proteins
(Table 1). The use of a small molecule to regulate either
protein stability or protein splicing provides a reasonably
rapid and specific degree of control over protein func-
tion. An essential protein could be expressed through
key developmental milestones, and could be reversibly
and conditionally inactivated at later time points. A sig-
nificant investment of effort is required to implement
these approaches in the least disruptive manner. How-
ever, the specificity that is achieved by targeting the
endogenous genetic locus makes these approaches
Review
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ture of potential targets that is the cellular environment.
When one takes a longer view of the challenge of inter-
rogating the roles of specific proteins, a disadvantage
appears when considering these modular approaches.
Many proteins play more than one role in cells, and
methods that control protein existence do not provide
an obvious mechanism to probe more than one function.
The case of one member of the phosphoinositide
3-kinase (PI3K) family is illustrative.
Several groups independently showed that KO mice
lacking PI3Kg were apparently healthy but had reduced
immune responses when challenged with inflammatory
stimuli [75–77]. This finding would suggest that specific
inhibitors of PI3Kg might be powerful anti-inflammatory
drugs. However, as time progressed and the mice were
monitored further, it became apparent that the PI3KgKO
mice had a cardiac defect characterized by increased
contractility [78]. This observation would understand-
ably reduce the attractiveness of PI3Kg as a potential
drug target. More recently, Hirsch and coworkers engi-
neered knockin mice in which the endogenous PI3Kg al-
lele was replaced with a mutated version that is catalyt-
ically inactive [79]. These kinase-dead knockin mice
retain their immunological defects, but do not display
the increased cardiac contractility observed in the
PI3Kg KO mice. Additional investigations into the mo-
lecular mechanisms of these two phenotypes showed
that PI3Kg played distinct, yet critical, roles in two sep-
arable processes.
PI3Kg interacts with PDE3B to regulate cAMP levels in
the heart to control contractility, and this role is indepen-
dent of its kinase activity. However, the lipid kinase activ-
ity of PI3Kg is required to generate phosphatidylinositol-
3,4,5-trisphosphate, which leads to activation of Erk and
MAP kinase family members. Thus, the kinase activity
PI3Kg is directly responsible for its role in inflammatory
responses. It is not clear how any one of the conditional
strategies for regulating protein function covered in this
review would have revealed these separable functions of
PI3Kg. Conditional inactivation of PI3Kg function would
be expected to give rise to both the immunological phe-
notype and the cardiac phenotype. It would not be im-
mediately obvious if these two phenotypes were (or
were not) mechanistically intertwined. On the other hand,
a cell-permeable inhibitor that was specific for PI3Kg
would be expected to reveal the immunological pheno-
type, but not the cardiac phenotype, even after pro-
longed administration.
In the case of PI3Kg, more than one approach was re-
quired to identify and illuminate two distinct functions of
this protein. Perturbing the functions of specific proteins
will become increasingly important as life scientists
seek to understand how networks of interacting proteins
give rise to complex biological behavior. There is plenty
of room for success, and multiple approaches will be
required to deconvolute the individual contributions of
different proteins in complex systems.
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